- If you are wondering whether Salesforce at around US$153.42 still offers solid value or has become a value trap, the key is to look past the headlines and focus on what the numbers are really saying.
- The stock has been under pressure recently, with the share price down 5.1% over the last week, 14.8% over the past month, and 39.5% year to date, contributing to a 42.9% decline over the past year and a 36.5% decline over five years.
- Recent coverage has focused on Salesforce as a major software provider adapting its product mix and business priorities. This has kept investor attention firmly on its long term relevance and competitive position. That context helps explain why sentiment and the stock price can shift quickly as the market reassesses how much it is willing to pay for that profile.
- Even after those moves, Salesforce currently holds a valuation score of 5 out of 6, suggesting that several standard checks point to potential undervaluation. The rest of this article will walk through those valuation methods and then finish with a broader way to think about what the stock might be worth.
Find out why Salesforce’s -42.9% return over the last year is lagging behind its peers.
Approach 1: Salesforce Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model estimates what Salesforce might be worth today by projecting its future cash flows and then discounting those back into present dollars. It is essentially asking what tomorrow’s cash is worth if you had it in your hand right now.
For Salesforce, the latest twelve month Free Cash Flow is about $14.5b. Analysts have provided several years of Free Cash Flow estimates, and Simply Wall St extends those out using its own assumptions, with projected Free Cash Flow of around $18.6b in 2031. These projections, along with further extrapolated cash flows into the mid 2030s, are combined in a 2 Stage Free Cash Flow to Equity model using cash flow projections as the core input.
When all of those expected cash flows are discounted back to today, the DCF model arrives at an estimated intrinsic value of about $288.84 per share. Compared with the recent share price around $153.42, this implies the stock screens as 46.9% undervalued on this method.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Salesforce is undervalued by 46.9%. Track this in your watchlist or portfolio, or discover 44 more high quality undervalued stocks.
Approach 2: Salesforce Price vs Earnings (P/E)
For a profitable company like Salesforce, the P/E ratio is a useful way to think about value because it compares what you pay per share with the earnings that each share generates. Investors typically accept a higher P/E when they expect stronger earnings growth or see lower risk, and look for a lower P/E when growth expectations are more modest or risks are higher.
Salesforce currently trades on a P/E of 15.66x. That sits below the broader Software industry average of 25.49x and well below the peer group average of 57.45x. These simple comparisons suggest the stock trades at a discount to many other profitable software companies, but they do not explain whether that gap is justified by differences in growth, profitability or risk.
To address that, Simply Wall St calculates a proprietary “Fair Ratio” for Salesforce of 32.91x. This figure reflects factors such as the company’s earnings growth profile, its industry, profit margins, market value and risk characteristics. Because it adjusts for these elements, the Fair Ratio can be a more tailored benchmark than raw peer or industry comparisons. Setting this Fair Ratio against the current P/E of 15.66x indicates that, on this metric, Salesforce screens as undervalued.
Result: UNDERVALUED
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.
Upgrade Your Decision Making: Choose your Salesforce Narrative
Earlier we mentioned that there is an even better way to understand what Salesforce might be worth. This is where Narratives come in as a simple way for you to attach a clear story to the numbers you already care about, such as fair value estimates and views on future revenue, earnings and margins.
A Narrative on Simply Wall St is essentially your Salesforce story written into a forecast. You spell out how you think the business evolves, link that to a financial model, and end up with a fair value that you can directly compare with today’s share price to help decide whether the stock appears cheap or expensive based on your assumptions.
These Narratives live in the Community section of the platform, are used by millions of investors, and update automatically when new filings, earnings or news come through. Your view on Salesforce therefore does not sit in a static spreadsheet, it stays in sync with fresh information.
For example, one Salesforce Narrative currently anchors on a fair value near US$160, with more cautious assumptions on growth, margins and P/E. Another at the high end sits around US$385, building in stronger revenue growth, margin expansion and a higher future multiple. Seeing those side by side helps you decide which story, and which fair value range, feels closer to your own view.
Do you think there’s more to the story for Salesforce? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
New:Manage All Your Stock Portfolios in One Place
We’ve created the ultimate portfolio companion for stock investors, and it’s free.
• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocks
Try a Demo Portfolio for Free
Have feedback on this article? Concerned about the content? Get in touch with us directly.Alternatively, email editorial-team@simplywallst.com
About NYSE:CRM
Salesforce
Provides customer relationship management technology services that connect companies and customers together in the United States, Europe, and the Asia Pacific.
See The Free Research Report
Undervalued with proven track record.
See The Free Research Report
Similar Companies
-
NasdaqGS:CDNS
Cadence Design Systems
-
NasdaqGS:INTU
Intuit
Market Insights
Watt’s left in the overcrowded power trade?
Richard Bowman
The gravity of the SpaceX IPORichard Bowman
Land of the rising yields 📈
Mitchell Lawler
Weekly Picks
Lou_Baseneseon Virtuix Holdings1 day ago
From a “Shark Tank” Snub to an Air Force “Yes”: Why Virtuix at $3.50 May Be the Market’sMost Mispriced AI Story
Fair Value:US$7.551.2% undervalued
3users have followed this narrative
0users have commented on this narrative
0users have liked this narrative
Investingwillyon Mastercard6 days ago
Mastercard: The Best Dividend Stock You’re Ignoring
Fair Value:US$75034.9% undervalued
21users have followed this narrative
0users have commented on this narrative
4users have liked this narrative
tripledubon Intuitabout 1 month ago
A Wonderful Business at a Not-So-Wonderful Price
Fair Value:US$56053.9% undervalued
49users have followed this narrative
2users have commented on this narrative
27users have liked this narrative
Taloson MindWalk Holdings6 days ago
The Asymmetric TechBio Play: MindWalk Holdings and the Valuation Disconnect
Fair Value:US$8.2782.0% undervalued
17users have followed this narrative
0users have commented on this narrative
5users have liked this narrative
Updated Narratives
AnimalDoctorKwonon Akebia Therapeuticsabout 3 hours ago
Vafseo and the Future of Renal Anemia Treatment – Akebia’s Vision for a $5B Kidney Disease Portfolio
Fair Value:US$77.2998.6% undervalued
6users have followed this narrative
0users have commented on this narrative
0users have liked this narrative
AnimalDoctorKwonon Mustang Bioabout 5 hours ago
A CAR-T Therapy Pipeline with Complete Remission (CR) Data Priced as a Negative Asset???
Fair Value:US$1.861.5% undervalued
1users have followed this narrative
0users have commented on this narrative
0users have liked this narrative
GavrielHon oOh!mediaabout 6 hours ago
oOh! Media Limited: Contested Takeover Creates an Asymmetric Upside
Fair Value:AU$1.924.2% undervalued
1users have followed this narrative
0users have commented on this narrative
0users have liked this narrative
